Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ


Friday, 17 May 2013 01:09am EDT 

Dow Jones reported that Sanofi SA announced a pivotal study examining JAK2 inhibitor SAR302503 for myelofibrosis (MF) had positive results. The primary endpoint assessed the proportion of patients achieving less than 35% reduction of spleen volume. Consistent with data reported in previous trials, the most common adverse events were anemia, diarrhea, nausea and vomiting. Full results will be presented at an upcoming medical congress. MF is a rare, debilitating and life-threatening hematologic malignancy characterized by abnormal blood cell production and scarring, or fibrosis, in the bone marrow. SAR302503 is an investigational, selective JAK2 inhibitor. The Company's Sanofi Oncology is developing SAR302503 for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis, including those previously treated with ruxolitinib; polycythemia vera; and essential thrombocythemia. 

Company Quote

74.77
0.75 +1.01%
16 Apr 2014